Literature DB >> 24575870

Ebola virus vaccines: an overview of current approaches.

Andrea Marzi1, Heinz Feldmann.   

Abstract

Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans and nonhuman primates. Although infections only occur frequently in Central Africa, the virus has the potential to spread globally and is classified as a category A pathogen that could be misused as a bioterrorism agent. As of today there is no vaccine or treatment licensed to counteract Ebola virus infections. DNA, subunit and several viral vector approaches, replicating and non-replicating, have been tested as potential vaccine platforms and their protective efficacy has been evaluated in nonhuman primate models for Ebola virus infections, which closely resemble disease progression in humans. Though these vaccine platforms seem to confer protection through different mechanisms, several of them are efficacious against lethal disease in nonhuman primates attesting that vaccination against Ebola virus infections is feasible.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24575870      PMCID: PMC4785864          DOI: 10.1586/14760584.2014.885841

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  72 in total

1.  Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro.

Authors:  K Aoki; C Barker; X Danthinne; M J Imperiale; G J Nabel
Journal:  Mol Med       Date:  1999-04       Impact factor: 6.354

2.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

3.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

4.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

5.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

8.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

Authors:  L Vanderzanden; M Bray; D Fuller; T Roberts; D Custer; K Spik; P Jahrling; J Huggins; A Schmaljohn; C Schmaljohn
Journal:  Virology       Date:  1998-06-20       Impact factor: 3.616

9.  A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Authors:  Yoshimi Tsuda; Patrizia Caposio; Christopher J Parkins; Sara Botto; Ilhem Messaoudi; Luka Cicin-Sain; Heinz Feldmann; Michael A Jarvis
Journal:  PLoS Negl Trop Dis       Date:  2011-08-09

10.  Evaluation in nonhuman primates of vaccines against Ebola virus.

Authors:  Thomas W Geisbert; Peter Pushko; Kevin Anderson; Jonathan Smith; Kelly J Davis; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

View more
  55 in total

Review 1.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

2.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Authors:  Edgar Davidson; Christopher Bryan; Rachel H Fong; Trevor Barnes; Jennifer M Pfaff; Manu Mabila; Joseph B Rucker; Benjamin J Doranz
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

3.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

4.  A vaccine against Ebola: Problems and opportunities.

Authors:  Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Preventing the emergence of Ebola disease in unaffected countries: necessity of preparedness.

Authors:  Saurabh RamBihariLal Shrivastava; Prateek Saurabh Shrivastava; Jegadeesh Ramasamy
Journal:  Int J Health Policy Manag       Date:  2014-11-01

6.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

7.  Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.

Authors:  Andrea Marzi; Peter Halfmann; Lindsay Hill-Batorski; Friederike Feldmann; W Lesley Shupert; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Science       Date:  2015-03-26       Impact factor: 47.728

Review 8.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

9.  An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Authors:  Reed F Johnson; Drishya Kurup; Katie R Hagen; Christine Fisher; Rohan Keshwara; Amy Papaneri; Donna L Perry; Kurt Cooper; Peter B Jahrling; Jonathan T Wang; Jan Ter Meulen; Christoph Wirblich; Matthias J Schnell
Journal:  J Infect Dis       Date:  2016-07-24       Impact factor: 5.226

10.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.